Business
RenovoRx Expands RenovoCath® Commercial Adoption to Nine Active Cancer Centers Including City of Hope Cancer Center and Moffitt Cancer Center
MOUNTAIN VIEW, Calif., Jan. 20, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies, today announced continued commercial momentum with a growing number of U.S. cancer centers now integrating the Company’s RenovoCath patented FDA-cleared drug-delivery device into oncology treatment programs. The Company’s TAMP™ (Trans-Arterial Micro-Perfusion) therapy platform, enabled by the RenovoCath de
About this update from Renovorx, Inc.
[{"type":"image","alt":"RenovoRx, Inc.","displaySize":"","headline":null,"caption":"RenovoRx, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":47,"url":"https://media.zenfs.com/en/globenewswire.com/ab41ac143cad3cd5a5d7e95f545a721c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/PIkpg_5WC5Ht6PAvrhd3Kg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTY2O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/ab41ac143cad3cd5a5d7e95f545a721c","width":300,"height":47}},"lazy":false},{"type":"text","content":"MOUNTAIN VIEW, Calif., Jan. 20, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies, today announced continued commercial momentum with a growing number of U.S. cancer centers now integrating the Company’s RenovoCath patented FDA-cleared drug-delivery device into oncology treatment programs. The Company’s TAMP™ (Trans-Arterial Micro-Perfusion) therapy platform, enabled by the RenovoCath device, is designed to deliver chemotherapy near the tumor site, potentially enhancing therapeutic effectiveness and minimizing the systemic side effects commonly associated with traditional intravenous chemotherapy administration.","length":734,"tagName":"p"},{"type":"text","content":"The number of active commercial cancer centers which are eligible to order and use RenovoCath has increased from five in September 2025 to nine currently and growing with the addition of City of Hope Cancer Center in Duarte, California and Moffitt Cancer Center in Tampa, Florida. This positive development is strong evidence that RenovoRx’s commercialization efforts for RenovoCath as a standalone device are taking hold in the market.","length":436,"tagName":"p"},{"type":"text","content":"City of Hope Cancer Center’s Chief of Interventional Radiology, Dr. Jonathan Kessler, was recently featured in an interview on Spectrum News 1 SoCal, highlighting how RenovoRx’s patented TAMP therapy platform, enabled by RenovoCath, has the potential to reshape oncology management for patients diagnosed with difficult-to-treat tumors, like locally advanced pancreatic cancer. View the full interview at: https://ir.renovorx.com/news-events/clinical-news/detail/21002/new-device-delivers-targeted-chemo-for-pancreatic-cancer.","length":526,"tagName":"p"},{"type":"text"...